Dyadic International, Inc. (DYAI)
Chart Events
Performance Outlook
| Previous Close | 2.1300 |
| Open | 2.1400 |
| Bid | 2.1200 x 800 |
| Ask | 2.1400 x 800 |
| Day's Range | 2.0900 - 2.1400 |
| 52 Week Range | 1.7400 - 6.8900 |
| Volume | |
| Avg. Volume | 63,454 |
| Market Cap | 59.528M |
| Beta (5Y Monthly) | 0.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3910 |
| Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.33 |
- Zacks Small Cap Research
DYAI: First Quarter 2022 Operational & Financial Results
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) released 2021 operational and financial results in a press release on May 12, 2022, subsequently filing its 10-Q with the SEC and hosting a conference call with investors. Highlights for the first quarter and to-date include: ➢ Exclusive animal health license agreement with Phibro -
- GlobeNewswire
Dyadic Reports First Quarter 2022 Financial Results and Highlights Recent Company Developments
New research, license, and collaboration agreement with a Global Food Ingredients Company using Dyadic’s proprietary biotechnologiesLicense agreement with Phibro/Abic Animal Health to develop and commercialize animal vaccine(s)Advancing first-in-human clinical trial application (CTA) to South African Health Products Regulatory Authority (SAHPRA) to support clinical safety of C1 produced proteinsC1 produced COVID-19 monoclonal antibody (mAb) demonstrated broad neutralization and protection agains
- GlobeNewswire
Dyadic Announces Research, License and Collaboration for the Manufacture of Animal Free Ingredients
JUPITER, Fla., May 11, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary protein production platform, today announced that it has entered into a Joint Development Agreement (“Agreement”) with a Global Food Ingredients Company to develop and manufacture a number of animal free ingredient products using the company’s biotechnologies.
